NEXI | NexImmune, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2651 - 0.3647
52 Week Range	0.2650 - 28.70
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	400
Average Volume	619,779
Shares Outstanding	1,394,670
Market Cap	508,636
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.02
Forward P/E Ratio	N/A
EPS	-18.51
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	USA
Website	NEXI

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NEXI's peers: RNAZ, SNSE, SRZN, XBIO

*Chart delayed

Analyzing fundamentals for NEXI we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NEXI Fundamentals page.

Watching at NEXI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NEXI Technicals page.